SELP and idiopathic pulmonary fibrosis: We have demonstrated platelet hyperactivity in patients with IPF using two mechanistically different agonists (ADP and TFLLR) and three different markers of platelet activation, namely platelet-monocyte aggregate formation, platelet P-selectin expression, and platelet fibrinogen binding.